|Bid||16.66 x 900|
|Ask||149.00 x 1000|
|Day's Range||21.36 - 22.62|
|52 Week Range||7.50 - 25.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.50|
GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018 at 9:05 am ET in New York.
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe ...
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 43 cents. GTx shares have increased 40 percent since the beginning of the year. The stock has more than tripled in the last ...
-- Completed patient enrollment in the ASTRID Trial, a Phase 2 double-blinded, placebo-controlled clinical trial of enobosarm in Stress Urinary Incontinence --
This was a multicenter, randomized, double blind, placebo controlled trial that enrolled a total of 108 subjects (83 women and 25 men) age ≥ 65 years of age who had suffered a hip fracture within the past three to seven weeks. Subjects were administered placebo or 0.5 mg, 1.0 mg, or 2.0 mg of VK5211 once-daily for 12 weeks (NCT02578095). The primary outcome of the trial was the change in lean body mass, less head, after 12 weeks of treatment.
GTx, Inc. today announced that it has been added to the Russell 3000® Index as part of the Russell U.S. Indexes annual reconstitution. The addition will take effect after the U.S.
GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 10:00 am ET in New York.
GTx, Inc. (GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI). The presentation, entitled Oral Enobosarm Shows Promising Activity in Post-Menopausal Women with Stress Urinary Incontinence: Results of a Phase 2 Study, took place at the 2018 American Urological Association annual meeting being held in San Francisco, CA, from May 18 to 21, 2018. “The overall treatment effect of enobosarm in this proof-of-concept trial demonstrates the potential of enobosarm to effectively treat SUI, the most common type of incontinence suffered by women,” said Kenneth M. Peters, M.D., Chairman of Urology, Oakland University William Beaumont School of Medicine, and the principal investigator in the trial.
Measuring GTx Inc’s (NASDAQ:GTXI) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 62 cents. GTx shares have risen 37 percent since the beginning of the year. The stock has more than quadrupled in the last ...
GTx, Inc. today reported financial results for the first quarter ended March 31, 2018 and highlighted recent accomplishments and upcoming milestones.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space. Here's a compilation of key biotech ...
GTx, Inc. today announced an upcoming podium presentation highlighting the clinical results from the Company’s open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence .
Stock Monitor: TapImmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on GTx, Inc. (NASDAQ: GTXI ). If you want access ...
GTx, Inc. today announced that it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence .
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 43 cents. For the year, the company reported that its loss widened to $30.4 million, or $1.75 per share. GTx shares have ...
GTx, Inc. today reported financial results for the fourth quarter and year ended December 31, 2017 and highlighted recent accomplishments and upcoming milestones.
It’s a big day for GTx, Inc. (NASDAQ:GTXI). The biopharmaceutical company released positive clinical data that had many, even some of the biggest bears on the stock, commending the headway GTx has made.
GTx, Inc. today announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence , including magnetic resonance imaging results from patients’ pelvic floor muscle.